The Business Research Company’s Drugs For Benign Prostatic Hypertrophy Global Market Report 2021 : COVID-19 Impact And Recovery
LONDON, GREATER LONDON , UK, August 30, 2021 /EINPresswire.com/ — Combination drugs are increasingly being used in the treatment of benign prostatic hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of benign prostatic hypertrophy.
Major players in the BPH drug industry are Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC.
Benign prostatic hypertrophy drugs manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate safety and efficacy of drugs using clinical trials data which will be assessed by competent authorities before authorizing for sale.
Read More On The Global Drugs For Benign Prostatic Hypertrophy Market Report:
The global drugs for benign prostatic hypertrophy market size are expected to grow from $4.15 billion in 2020 to $4.79 billion in 2021 at a compound annual growth rate (CAGR) of 15.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The BPH drugs market is expected to reach $6.3 billion in 2025 at a CAGR of 7.1%.
The drugs for benign prostatic hypertrophy market consist of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign prostatic hypertrophy is commonly seen in men older than age 50.
TBRC’s global drugs for benign prostatic hypertrophy market report is segmented by type into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, others, by end user into hospital pharmacies, retail pharmacies, others, by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.
Drugs For Benign Prostatic Hypertrophy Global Market Report 2021 – By Type (Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor), By End User (Hospital Pharmacies, Retail Pharmacies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), COVID-19 Impact And Recovery is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market overview, forecast drugs for benign prostatic hypertrophy market size and growth for the whole market, drugs for benign prostatic hypertrophy market segments, and geographies, drugs for benign prostatic hypertrophy market trends, drugs for benign prostatic hypertrophy market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Drugs For Benign Prostatic Hypertrophy Market Report:
Here Is A List Of Similar Reports By The Business Research Company:
Genito-Urinary Drugs Global Market Report 2021 – By Type (Hormonal Contraceptives, Drugs For Benign Prostatic Hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), COVID-19 Impact And Recovery
Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2021 – By Product (Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants), By End-User (Hospitals, Ambulatory Surgical Centers (ASC), Clinics, Home), By Procedure Type (Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery), COVID-19 Impact And Recovery
Generic Pharmaceuticals Global Market Report 2021 – By Therapy (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Type (Biosimilar, Simple Generic, Super Generic), By Drug Delivery (Oral, Injectables, Dermal/Topical, Inhaler), COVID-19 Growth And Change
Interested to know more about The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Or get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293